The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...

The percentage of overweight or obese adults prescribed GLP-1s jumped by almost 587% between 2019 and 2024, according to a ...

Cigna's Evernorth business caps GLP-1 drug copays at $200 or less ... monthly out-of-pocket expenses for weight-loss drugs Zepbound and Wegovy to $200. Beginning in the second half of 2025 ...

Eli Lilly is claiming another victory in a head-to-head trial comparing its weight-loss drug Zepbound to its main rival Wegovy from Novo Nordisk. The full data from the 751-subject SURMOUNT-5 ...

These companies, like the rest of the insurance sector, have reported overwhelming utilization of $1,000-per-month medications including Wegovy, Zepbound ... Group, Cigna and CVS Health, which ...

Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo Nordisk, after negotiating a price cut with the company, along with Novo ...

Novo Nordisk’s weight-loss drug Wegovy has been surpassed in weekly U.S. prescriptions by Eli Lilly’s Zepbound, and now the company is trying to get back on track. LLY inks $1B deal to acquire ...

Another drug called Zepbound contains the same active ingredient ... (Note: Optum Perks coupons cannot be used with any insurance copays or benefits.) Mounjaro is a type of drug called a GLP ...